Usefulness of body surface mapping to differentiate patients with Brugada syndrome from patients with asymptomatic Brugada syndrome

Acta Medica Okayama

Volumn 58, Issue 1, 2004, Pages 29-35

  Hisamatsu, Kenichi ^a   Kusano, Kengo Fukushima ^a   Morita, Hiroshi ^a   Takenaka, Shiho ^a   Nagase, Satoshi ^a   Nakamura, Kazufumi ^a   Emori, Tetsuro ^a   Matsubara, Hiromi ^a   Ohe, Tohru ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Asymptomatic brugada syndrome; Body surface map; Brugada syndrome; Ic antiarrhythmic drugs

Indexed keywords

ANTIARRHYTHMIC AGENT;

ADULT; ARTICLE; BODY SURFACE; BRUGADA SYNDROME; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ELECTROCARDIOGRAM; HUMAN; ST SEGMENT ELEVATION; SYMPTOMATOLOGY;

ADULT; ANTI-ARRHYTHMIA AGENTS; BODY SURFACE POTENTIAL MAPPING; BUNDLE-BRANCH BLOCK; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; HUMANS; MIDDLE AGED; SYNDROME; VENTRICULAR FIBRILLATION;

EID: 1642485738     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Brugada P and Brugada J: Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol (1992) 20: 1391-1396.
2. Brugada J, Brugada R, Antzelevitch C, Towbin J, Nademanee K and Brugada P: Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation (2002) 105: 73-78.
3. Priori SG, Napolitano C, Gasparini M, Pappone C, Della Bella P, Giordano U, Bloise R, Giustetto C, De Nardis R, Grillo M, Ronchetti E, Faggiano G and Nastoli J: Natural history of Brugada syndrome: Insights for risk stratification and management. Circulation (2002) 105: 1342-1347.
4. Takenaka S, Kusano KF, Hisamatsu K, Nagase S, Nakamura K, Morita H, Matsubara H, Emori T and Ohe T: Relatively benign clinical course in asymptomatic patients with brugada-type electrocardiogram without family history of sudden death. J Cardiovasc Electrophysiol (2001) 12: 2-6.
5. Shimizu W, Matsuo K, Takagi M, Tanabe Y, Aiba T, Taguchi A, Suyama K, Kurita T, Aihara N and Kamakura S: Body surface distribution and response to drugs of ST segment elevation in Brugada syndrome: Clinical implication of eighty-seven-lead body surface potential mapping and its application to twelve-lead electrocardiograms. J Cardiovasc Electrophysiol (2000) 11: 396-404.
6. Bruns HJ, Eckardt L, Vahlhaus C, Schulze-Bahr E, Haverkamp W, Borggrefe M, Breithardt G and Wichter T: Body surface potential mapping in patients with Brugada syndrome: Right precordial ST segment variations and reverse changes in left precordial leads. Cardiovasc Res (2002) 54: 58-66.
7. Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, Potenza D, Moya A, Borggrefe M, Breithardt G, Ortiz-Lopez R, Wang Z, Antzelevitch C, O'Brien RE, Schulze-Bahr E, Keating MT, Towbin JA and Wang Q: Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature (1998) 392: 293-296.
8. + channel mutation causing both long-QT and Brugada syndromes. Circ Res (1999) 85: 1206-1213.
9. Deschenes I, Baroudi G, Berthet M, Barde I, Chalvidan T, Denjoy I, Guicheney P and Chahine M: Electrophysiological characterization of SCN5A mutations causing long QT (E1784K) and Brugada (R1512W and R1432G) syndromes. Cardionvasc Res (2000) 46: 55-65.
10. Rook MB, Bezzina Alshinawi C, Groenewegen WA, van Gelder IC, van Ginneken AC, Jongsma HJ, Mannens MM and Wilde AA: Human SCN5A gene mutations alter cardiac sodium channel kinetics and are associated with the Brugada syndrome. Cardiovasc Res (1999) 44: 507-517.
11. Roden DM and Wilde AA: Drug-induced J point elevation: A marker for genetic risk of sudden death or ECG curiosity? J Cardiovasc Electrophysiol (1999) 10: 219-223.
12. to and action potential notch are smaller in left vs. right canine ventricular epicardium. Am J Physiol (1996) 271: H548-561.
13. Priori SG, Napolitano C, Schwartz PJ, Bloise R, Crotti L and Ronchetti E: The elusive link between LQT3 and Brugada syndrome: The role of flecainide challenge. Circulation (2000) 102: 945-947.
14. Fujiki A, Usui M, Nagasawa H, Mizumaki K, Hayashi H and Inoue H: ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: Insight into the mechanism of Brugada syndrome. J Cardiovasc Electrophysiol (1999) 10: 214-218.
15. Krishnan SC and Josephson ME: ST segment elevation induced by class IC antiarrhythmic agents: Underlying electrophysiologic mechanisms and insights into drug-induced proarrhythmia. J Cardiovasc Electrophysiol (1998) 9: 1167-1172.
16. Morita H, Takenaka-Morita S, Fukushima-Kusano K, Kobayashi M, Nagase S, Kakishita M, Nakamura K, Emori T, Matsubara H and Ohe T: Risk stratification for asymptomatic patients with Brugada syndrome. Circ J (2003) 67: 312-316.
17. Nagase S, Kusano KF, Morita H, Fujimoto Y, Kakishita M, Nakamura K, Emori T, Matsubara H and Ohe T: Epicardial electrogram of the right ventricular outflow tract in patients with the Brugada syndrome. Using the epicardial lead. J Am Coll Cardiol (2002) 39: 1992-1995.
18. Miyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y and Ogawa S: Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol (1996) 27: 1061-1070.
19. Kasanuki H, Ohnishi S, Ohtuka M, Matsuda N, Nirei T, Isogai R, Shoda M, Toyoshima Y and Hosoda S: Idiopathic ventricular fibrillation induced with vagal activity in patients without obvious heart disease. Circulation (1997) 95: 2277-2285.
20. Brugada J and Brugada P: Further characterization of the syndrome of right bundle branch block, ST segment elevation, and sudden cardiac death. J Cardiovasc Electrophysiol (1997) 8: 325-331.